Develop an ornamental genetic modification enzyme targeted therapy! Imago completes $80 million...

Text . . On November 19th Imago BioSciences announced the completion of an $80 million round of C financing.
round of financing is led by Farallon Capital Management, followed by T. Rowe Price Associates, Surveyor Capital, Irving Investors and Kingdon Capital Management.
Imago will use the proceeds to complete a clinical Phase III study of the drug bomedemstat to treat bone marrow proliferating tumors.
: Imago's official website, Iago, based in San Francisco, USA, is committed to discovering and developing new treatments for blood diseases targeted by an oscic genetic modifier enzyme, having previously completed rounds of financing for $66.5 million in rounds of A and B and plans to launch an IPO next year.
Bomedemstat (IMG-7289) is an oral small molecule LSD1 inhibitor.
LSD1 is an osctopic genetic modification enzyme that is critical to the maturation and normal activity of giant nucleocytes and the self-renewal of malignant hematopoietic dry/progenitic cells, specifically removing methyl groups from lysine in histones and other chromatin-binding proteins, where methyl markers at specific locations regulate the properties and fate of blood cells.
addition, LSD1 and JAK-STAT pathflytes together regulate inflammatory cytokines and growth factor expression in cytocytocytes, which are widely believed to be the main sources of pathogenic growth factors and cytokines for bone marrow fibrosis.
source: Imago's official website, Bomedemstat, is being tested in two clinical Phase II trials for bone marrow fibrosis and primary plate plateroid .b, respectively.
for both adaptations, Bomedemstat has been awarded fast-track and orphan drug eligibility by the FDA, and the EMA has also granted Bomedemstat "priority drug" status for the treatment of bone marrow fibrosis.
data for the study will be released orally at the annual meeting of the American Society of Hematology (ASH) on December 5 this year.
source: Imago's official website, Bomedemstat, and JAK inhibitor reedtinib are also undergoing clinical trials, and research on sickle cell disease and solid tumors is advancing, but will not be clinical until 2022 at the earliest.
funding will support us in developing transformative drugs to treat people with malignant bone marrow cancer and move Bomedemstat to the next phase of clinical trials with multiple adaptations," he said.
," said Dr. Hugh Young Rienhoff Jr., Ceo of Imago.
: 1 s IMAGO BIOSCIENCES RAISES $80 MILLION IN SERIES C FINANCING (Source: Imago.com) 2 s Blood cancer player Imago Biosciences caps off an $80M Series C with an IPO promise for 2021 (Source: Endpoints News) Original title: Development of Oscic genetic modification enzyme targeting therapy! Imago completed an $80 million round C financing with the goal of transforming blood cancer treatment